Table 1

Previously reported outcomes of tranexamic acid (TXA) in hip fracture patients

Use of TXA in patients with hip fractures
	Country	Design	Hip fx (IT or FNF)	TXA regimen	DVT PPX	Sample size	Blood loss (cc)	Transfuse rate %	Thromboembolic events
Lee et al 201511	UK	Cohort	Hemiarthroplasy only	1 g bolus preoperative	Tinzaparin	84 cases/187 controls	–	6	1
Lee et al 201511	UK	Cohort	Hemiarthroplasy only	1 g bolus preoperative	Tinzaparin	84 cases/187 controls	–	19	4
Emara et al 20149	Egypt	RCT	Hemiarthroplasty only	10 mg/kg bolus, then 5 mg/kg/hour infusion	Clexane	20 cases IV/20 cases topical/20 controls	640*	5	5
Emara et al 20149	Egypt	RCT	Hemiarthroplasty only	10 mg/kg bolus, then 5 mg/kg/hour infusion	Clexane	20 cases IV/20 cases topical/20 controls	1100*	32	0
Zufferey et al 201010	France	RCT	Hip fractures	15 mg/kg bolus preoperative and 3 h later	Fondaparinux×35 days (mandatory ultrasound)	57 cases/53 controls	975	42	0
Zufferey et al 201010	France	RCT	Hip fractures	15 mg/kg bolus preoperative and 3 h later	Fondaparinux×35 days (mandatory ultrasound)	57 cases/53 controls	1178	60	0
Sadeghi and Mehr-Aein 20068	Iran	RCT	Hip fractures	15 mg/kg bolus preoperative	NA	32 cases/35 controls	960	37	0
Sadeghi and Mehr-Aein 20068	Iran	RCT	Hip fractures	15 mg/kg bolus preoperative	NA	32 cases/35 controls	1484	57	0
Vijay et al 201335	India	RCT	Hip fractures	10 mg/kg bolus at surgery	NA	45 cases/45 controls	39*	16	0
Vijay et al 201335	India	RCT	Hip fractures	10 mg/kg bolus at surgery	NA	45 cases/45 controls	91*	40	0

*Drain output. Thromboembolic events include only symptomatic thromboembolic events.
DVT, deep vein thrombosis; FNF, femoral neck fracture; IT, intertrochanteric; NA, not applicable; PPX, prophylaxis; RCT, randomised controlled trial.